Rhythm Pharmaceuticals Announces Presentation of New Data at ObesityWeek® 2026
Key Highlights
- ➤TRANSCEND continuous setmelanotide therapy cut BMI 18.8% at two years
- ➤Placebo-switch patients saw a 16.5% mean BMI reduction at two years
- ➤Adult continuous-treatment patients achieved a 21.2% mean BMI reduction
- ➤Global panel of 17 experts established acquired HO diagnostic criteria
- ➤Setmelanotide safety profile generally matched previous acquired HO trials
Expert Statements
David Meeker, Chairman, President and Chief Executive Officer of Rhythm Pharmaceuticals
“The data presented at ObesityWeek add to our understanding of acquired HO and the potential benefits of setmelanotide”
David Meeker, Chairman, President and Chief Executive Officer of Rhythm Pharmaceuticals
“The sustained BMI reductions at two years in TRANSCEND build on the robust efficacy demonstrated in our pivotal Phase 3 trial.”
David Meeker, Chairman, President and Chief Executive Officer of Rhythm Pharmaceuticals
“And, importantly, the new global expert consensus on the definition and diagnosis of acquired HO represents an important step toward better recognition and more consistent diagnosis of this serious disease, helping patients receive the care they need.”
Christian Roth, M.D., pediatric endocrinologist and principal investigator of the Norcliffe Foundation Center for Integrative Brain Research at Seattle Children’s Research Institute
“Acquired hypothalamic obesity is a complex disease that can be difficult to recognize because patients experience varying patterns of weight gain following hypothalamic injury”
Christian Roth, M.D., pediatric endocrinologist and principal investigator of the Norcliffe Foundation Center for Integrative Brain Research at Seattle Children’s Research Institute
“By establishing evidence-informed diagnostic criteria, we hope to help clinicians identify the condition earlier, distinguish it from other forms of obesity and connect patients with appropriate, disease-specific care.”
– Two-year results from Phase 3 TRANSCEND trial showed continuous setmelanotide therapy sustained BMI reductions in patients with acquired hypothalamic obesity –
– Global expert panel established and presented consensus definition, diagnostic criteria for acquired hypothalamic obesity –
Get started
Create a free account to read the full story.
